-
1 Comment
NeuroMetrix, Inc is currently in a long term uptrend where the price is trading 14.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
NeuroMetrix, Inc's total revenue rose by 6.0% to $2M since the same quarter in the previous year.
Its net income has increased by 100.2% to $2K since the same quarter in the previous year.
Finally, its free cash flow grew by 513.3% to $281K since the same quarter in the previous year.
Based on the above factors, NeuroMetrix, Inc gets an overall score of 5/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US6412558073 |
Sector | Healthcare |
Industry | Medical Devices |
Beta | 1.83 |
---|---|
Market Cap | 9M |
PE Ratio | None |
Target Price | 50 |
Dividend Yield | None |
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for NURO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025